You have read all your free articles, to continue reading subscribe to read the rest of this content.
GlaxoSmithKline (GSK) and Merck have entered into a global strategic alliance to jointly develop and commercialise M7824, an investigational bifunctional fusion protein immunotherapy that is currently in clinical development, including potential registration studies, for multiple difficult-to-treat
Related Posts
How will Brexit affect the pharmaceutical sector? Brexit and the implications of the UK’s departure from the European Union (EU) continue to dominate the news agenda and industry discussions. Here, Thomas Beck, Senior Vice President, Quality Management at Recipharm, gives his views on the relocAlready a subscriber Login You have…
The company announced earlier this summer that it has entered into an agreement to acquire Spitfire Pharma, Inc. (Spitfire) including its product candidate SP-1373 (to be renamed ALT-801), a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH). SpitfAlready a subscriber Login You have read all your free…
Following a 70-year effort, China has been awarded a malaria-free certification from WHO. This is a notable feat for a country that reported 30 million cases of the disease annually in the 1940s, the WHO states in a press release. “Today we congratulate the people of China on ridding the…
Sanofi will acquire the Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), just a few days after the company turned down Novo Nordisk's bid. The acquisition is Sanofi's second major takeover deal this month following its acquisition of Bioverativ. “Since our founding in 20Already a subscriber Login You have…